News
Movano Health establishes medical advisory board ahead of product launch
The US healthcare company Movano Health has announced the formation of its medical advisory board ahead of bringing its “medical-grade” wearable to market.
The initial panel will be composed of healthcare industry subject matter experts in women’s health, mental health, and sleep, who will serve as advisors to the Evie team regarding the development of its “medical-grade” smart ring for women.
The inaugural members of the medical advisory board will include:
Dr Mary Claire Haver – a board-certified OB/GYN, author and entrepreneur, who has devoted her practice to women’s health.
She has helped women going through perimenopause and menopause actualise their health and wellness goals by creating The Galveston Diet integrated wellness program.
With the goal of empowering and educating women, Dr Haver took a deep dive into the science of menopause, ageing, and inflammation beyond what she was taught in medical school and residency. She emerged with an programmed so women could wisely invest in their most undervalued asset, their health.
Dr Ruth C. White – a mental health expert, stress management advocate and diversity trainer who authored the book, The Stress Management Workbook: De-stress in 10 minutes or Less.
Throughout her career, she has spent more than 20 years teaching social work at the University of Southern California, Seattle University, UC Berkeley, Fordham, and San Francisco State. Her holistic, science-based, prevention-focused approach is grounded in her experience as an elite athlete and her personal mental health journey.
Dr Andrea Matsumurais – a sleep medicine specialist at the Oregon Clinic.
Her work focuses specifically on sleep in women and how their sleep differs from that of men. She practiced medicine as a primary care physician for 12 years until she realised that the root of managing chronic conditions hinges on getting a good night’s rest.
Stacy Salvi, vice president of strategy at Movano Health, said: “To develop a wearable that is truly medical grade, we needed to make sure we involved the experts.
“This highly regarded group of advisors are in a unique position to provide perspective from their day-to-day interactions with women which will enhance Evie’s product experience.
“We are honoured to work closely with each of them and tap their unparalleled expertise to help women better understand their bodies.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






